Finasteride Three Times Weekly is NOT Recommended for Androgenetic Alopecia
Based on current evidence, finasteride three times per week is not an established or recommended regimen for hair regrowth and maintenance in androgenetic alopecia—you should use daily dosing instead. The FDA-approved dosing is 1 mg daily for male pattern baldness or 5 mg daily for benign prostatic hyperplasia 1. No high-quality evidence supports the efficacy of a three-times-weekly finasteride regimen.
Why Daily Dosing is Required
The pharmacology of finasteride demands consistent daily administration. Finasteride works by competitively inhibiting Type II 5α-reductase, forming a stable enzyme complex with extremely slow turnover (half-life ~30 days) 1. While this long half-life might theoretically support less frequent dosing, the clinical evidence base is built entirely on daily regimens.
Key pharmacodynamic facts:
- A single 5 mg dose produces maximum DHT suppression at 8 hours, maintained throughout 24 hours 1
- Daily dosing at 5 mg reduces serum DHT by approximately 70% after up to 4 years 1
- Discontinuation returns DHT levels to baseline in approximately 2 weeks 1
The Evidence Gap for Intermittent Dosing
The only relevant study examining non-daily finasteride is an every-other-month (EOM) maintenance regimen, not three-times-weekly 2. This 2024 study showed that after 1 year of daily finasteride 1 mg establishing initial response, switching to EOM dosing maintained similar photographic improvements compared to continued daily dosing. However, critically, the EOM group showed decreased hair density and elevated DHT and DHT/testosterone ratio, while the daily group showed elevated hair density and lower DHT 2.
This suggests that even with established response, reducing frequency compromises biochemical control and objective hair density metrics.
What About Dutasteride Intermittent Dosing?
A 2025 pilot study examined dutasteride (a more potent dual 5α-reductase inhibitor) at twice-weekly and thrice-weekly regimens 3. While both intermittent dutasteride regimens increased hair growth in a dose-dependent manner, this does NOT translate to finasteride for several reasons:
- Dutasteride has a much longer half-life than finasteride (approximately 5 weeks vs. 5-6 hours) 4
- Dutasteride inhibits both Type I and Type II 5α-reductase, while finasteride only inhibits Type II 4
- The study used dutasteride 0.5 mg (equivalent to much higher finasteride doses in potency)
You cannot extrapolate dutasteride intermittent dosing data to finasteride—the pharmacokinetics are fundamentally different.
Clinical Recommendations
For Men with Androgenetic Alopecia:
- Use finasteride 1 mg daily as the evidence-based regimen 1
- Expect to see results after at least 3-6 months of consistent daily use
- Continue indefinitely for maintenance—discontinuation leads to reversal of benefits within months 1
For Women (if considering off-label use):
- Evidence is mixed and dose-dependent 4
- Postmenopausal women: 2.5-5 mg daily showed benefit in some studies (not 1 mg) 4
- Premenopausal women: Limited data, inconsistent results, and absolute contraindication in pregnancy due to teratogenic risk 4
- Strict contraception required during and for at least 30 days after discontinuation 4
Common Pitfalls to Avoid
Don't reduce frequency without establishing initial response: The EOM study only tested maintenance after 1 year of daily therapy 2
Don't confuse dutasteride and finasteride dosing: Their different pharmacokinetics mean intermittent regimens cannot be interchanged 3
Don't expect rapid results: Hair growth cycles require months to show visible improvement—premature discontinuation is common
Monitor for sexual side effects: These occur in a minority but can persist after discontinuation in rare cases 1
Counsel about PSA reduction: Finasteride reduces PSA by approximately 50% after 12 months, which must be considered in prostate cancer screening 5
The Bottom Line
Stick with daily finasteride 1 mg for male pattern baldness. Three-times-weekly dosing lacks any supporting evidence and risks suboptimal DHT suppression, potentially compromising both hair regrowth and maintenance. The only scenario where less-than-daily dosing has been studied is every-other-month maintenance after 1 year of daily therapy, and even then, objective measures showed inferior results 2.